Brookline initiated coverage of SAB Biotherapeutics with a Buy rating and $8 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics Appoints Mr. Conley, Details Public Disclosure
- SAB Biotherapeutics Announces Departure of Chief Financial Officer
- FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
- SAB Biotherapeutics announces FDA clearance for SAB-142 IND application
- SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates